News Releases

News Releases

Date Title
Jul 26, 2021 Sesen Bio Announces Significant Commercial Progress as the Company Approaches the Potential Approval and Launch of Vicineum™ in the US
Hiring of the US sales force is 97% complete and sales training has commenced 14 Key Opinion Leader (KOL) speakers have been identified and speaker training has commenced Two-pronged market access and reimbursement strategy has commenced CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul.
Jul 21, 2021 Sesen Bio Announces New Appointments to its Board of Directors
Peter K Honig, MD, MPH and Michael A.S. Jewett , MD, FRCSC, FACS have joined the Sesen Bio Board of Directors as the Company nears potential US approval of Vicineum™ in August 2021 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 21, 2021-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company
Jul 20, 2021 Sesen Bio and Qilu Pharmaceutical Announce Enrollment of First Patient in Clinical Trial for Vicineum™ in China
Anticipated submission of product market application for Vicineum in China in 2022, with potential approval in 2023 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 20, 2021-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of
Jul 14, 2021 Sesen Bio Announces Productive Late-Cycle Meeting with the FDA for Vicineum™
No Advisory Committee meeting is planned at this time No confirmatory trial required at this time Company believes it remains on track for August 18 th target PDUFA date CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 14, 2021-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted
Jul 2, 2021 Sesen Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 2, 2021-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported the grants of non-statutory stock options to four new employees in connection with
Jun 18, 2021 Sesen Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 18, 2021-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported the grant of a non-statutory stock option to one new employee in connection with the
Jun 2, 2021 Sesen Bio Announces Global Supply Partnership with Qilu Pharmaceutical
Technology transfer to Qilu Pharmaceutical on track for completion in 2021 Sesen Bio to receive $2M milestone payment upon completion of technology transfer CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 2, 2021-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein
Jun 1, 2021 Sesen Bio Strengthens Senior Leadership Team
Company hires four experienced leaders across commercial, medical and human resources functions as it works towards launch readiness Company remains on track for potential approval of Vicineum™ in the US in August 2021 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun.
May 27, 2021 Dr. Thomas Cannell, President and CEO of Sesen Bio, to Participate in Fireside Chat at the 2021 Jefferies Virtual Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 27, 2021-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that Sesen Bio President and CEO Dr.
May 21, 2021 Sesen Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 21, 2021-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported the grant of a non-statutory stock option to one new employee in connection with the
Displaying 1 - 10 of 25

© 2021 Sesen Bio. All Rights Reserved.

Top